KROS Begins Dosing in Phase II Study With Rinvatercept in DMD
Keros Therapeutics begins dosing in a phase II study of rinvatercept in DMD patients, with initial data expected in the first half of 2027.
KROS - Keros Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$20.33
DETAILS
HIGH:
$23.00
LOW:
$18.00
MEDIAN:
$20.00
CONSENSUS:
$20.33
UPSIDE:
78.96%
Stock News
Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda
LEXINGTON, Mass., Sept. 29, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that it expects to receive a $20 million development milestone payment under the terms of the license agreement of elritercept with partner Takeda, following the dosing of the first patient in the ELRiSE MF clinical trial. ELRiSE MF is a Phase 3, multicenter, double-blind, randomized trial to compare the efficacy and safety of elritercept to placebo in patients with myelofibrosis (“MF”) and anemia on concurrent ruxolitinib therapy.
Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD
LEXINGTON, Mass., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that the first patient was dosed in the Phase 2 clinical trial of rinvatercept in patients with Duchenne muscular dystrophy (“DMD”).
Keros Therapeutics Announces $5 Million Share Repurchase Authorization
LEXINGTON, Mass., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that its Board of Directors has approved a $5 million share repurchase program of the Company's common stock following receipt of a $20 million development milestone payment under the license agreement of elritercept with Takeda Pharmaceuticals U.S.A., Inc., following the dosing of the first patient in the ELRiSE MDS clinical trial. This approval grants Keros' management the authority to repurchase outstanding shares of the Company's common stock, from time to time, in the open market and/or by such other means in accordance with applicable state and federal securities laws.
Why Is Keros Therapeutics (KROS) Up 8% Since Last Earnings Report?
Keros Therapeutics (KROS) reported earnings 30 days ago. What's next for the stock?
Hsbc Holdings PLC Makes New $761,000 Investment in Keros Therapeutics, Inc. $KROS
Hsbc Holdings PLC acquired a new position in Keros Therapeutics, Inc. (NASDAQ: KROS) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 69,926 shares of the company's stock, valued at approximately $761,000. Hsbc Holdings PLC owned about 0.35% of Keros Therapeutics as
Should You Buy KROS Stock as Pipeline Promise Meets Revenue Risk?
Keros' rinvatercept pipeline offers upside, but zero quarterly revenue, clinical risk and a premium valuation make the stock a cautious bet.
KROS $20M Takeda Milestone Adds Cash but Revenue Visibility Stays Weak
Keros gets a $20M Takeda milestone, boosting cash and flexibility, but weak revenue visibility keeps collaboration income in focus.
Keros Therapeutics, Inc. $KROS Shares Acquired by Dimensional Fund Advisors LP
Dimensional Fund Advisors LP lifted its holdings in Keros Therapeutics, Inc. (NASDAQ: KROS) by 453.9% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 321,360 shares of the company's stock after buying an additional 263,347 shares during
Keros Therapeutics, Inc. $KROS Shares Acquired by Empowered Funds LLC
Empowered Funds LLC raised its holdings in Keros Therapeutics, Inc. (NASDAQ: KROS) by 142.2% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 145,517 shares of the company's stock after purchasing an additional 85,439 shares during the period. Empowered
KROS Q2 Earnings Miss as Revenues Fall to Zero, Pipeline in Focus
Keros posts a wider Q2 loss as revenues fall to zero, while cash runway into H1 2028 and rinvatercept pipeline milestones keep attention on future growth.
Keros Therapeutics Reports Second Quarter 2026 Financial Results
LEXINGTON, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today provided a business update and reported financial results for the quarter ended June 30, 2026.
Keros Therapeutics to Receive Development Milestone Payment from Partner Takeda
LEXINGTON, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that it will receive a $20 million development milestone payment under the terms of the license agreement of elritercept with partner Takeda, following the dosing of the first patient in the ELRiSE MDS clinical trial. ELRiSE MDS is a Phase 3, multicenter, open-label, randomized trial to compare the efficacy and safety of elritercept versus epoetin alfa for the treatment of anemia due to very low, low, or intermediate risk myelodysplastic syndromes (“MDS”).
New Strong Sell Stocks for July 30th
ITRG, BEEM and KROS have been added to the Zacks Rank #5 (Strong Sell) List on July 30, 2026.
Keros Therapeutics Appoints Anne Prener to its Board of Directors
LEXINGTON, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced the appointment of Anne Prener, M.D., Ph.D., to its Board of Directors, effective July 1, 2026.
Keros Therapeutics, Inc. (KROS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Keros Therapeutics, Inc. (KROS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Keros Therapeutics Announces Participation at Goldman Sachs 47th Annual Global Healthcare Conference
LEXINGTON, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros' President and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in a fireside chat presentation at the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026 at 4:00 p.m. Eastern time.
Should You Buy KROS After Q1 Miss and Takeda Deal Reset?
Keros faces a volatile setup after its Q1 miss, with a longer cash runway and leaner costs balanced against uncertain milestone-driven revenue.
KROS Turns to Next Wave of TGF-Beta Muscle Therapies
Keros is shifting toward rinvatercept-led neuromuscular development, with phase II plans, early human signals and cash runway shaping the KROS story.
KROS Stock Guide to Rinvatercept in DMD and ALS for 2026
Keros heads into 2026 with rinvatercept catalysts in DMD and ALS as investors watch phase II plans, orphan status and early clinical signals.
Price Targets
Keros Therapeutics price target lowered to $18 from $20 at Wells Fargo
$18.00
(was $10.11)
Benjamin Burnett
·
Wells Fargo
H.C. Wainwright Reiterates Buy Rating on Keros Therapeutics (KROS)
$20.00
(was $10.11)
Andrew Fein
·
H.C. Wainwright
Keros Therapeutics price target lowered to $23 from $30 at Leerink
$23.00
(was $10.11)
Leerink Partners
Jefferies Starts Keros Therapeutics (KROS) at Buy
$107.00
(was $62.02)
Kelly Shi
·
Jefferies
Truist Securities Reiterates Buy Rating on Keros Therapeutics (KROS)
$100.00
(was $62.02)
Srikripa Devarakonda
·
Truist Financial
Guggenheim Starts Keros Therapeutics (KROS) at Buy
$96.00
(was $55.80)
Vamil Divan
·
Guggenheim
Piper Sandler Reiterates Overweight Rating on Keros Therapeutics (KROS)
$105.00
(was $44.65)
Joseph Catanzaro
·
Piper Sandler
BTIG Maintains Buy on Keros Therapeutics, Raises Price Target to $105
$105.00
(was $49.98)
BTIG
Keros Therapeutics (KROS) Stock: Why It Surged 11.43% Today
$80.00
(was $31.79)
Julian Harrison
·
BTIG
Keros Therapeutics price target raised to $120 from $90 at Piper Sandler
$120.00
(was $39.92)
Joseph Catanzaro
·
Piper Sandler